Immunome’s (IMNM) “Outperform” Rating Reiterated at Wedbush

Wedbush restated their outperform rating on shares of Immunome (NASDAQ:IMNM) in a research note published on Thursday morning,Benzinga reports. The brokerage currently has a $33.00 target price on the stock.

Several other equities analysts have also issued reports on IMNM. Stephens reaffirmed an “overweight” rating and issued a $30.00 target price on shares of Immunome in a report on Thursday. Lifesci Capital initiated coverage on Immunome in a report on Tuesday, March 11th. They set an “outperform” rating and a $20.00 price objective for the company. Finally, Guggenheim reduced their price objective on Immunome from $35.00 to $25.00 and set a “buy” rating for the company in a report on Thursday. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $25.50.

Immunome Stock Down 5.5 %

IMNM stock opened at $8.18 on Thursday. The firm has a market cap of $652.58 million, a PE ratio of -1.01 and a beta of 1.93. The business has a 50 day moving average of $9.76 and a 200-day moving average of $11.55. Immunome has a 12-month low of $8.17 and a 12-month high of $26.70.

Immunome (NASDAQ:IMNM) last released its earnings results on Wednesday, March 19th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.16). The business had revenue of $2.74 million during the quarter, compared to the consensus estimate of $3.07 million. Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. On average, research analysts expect that Immunome will post -2.21 earnings per share for the current year.

Insider Buying and Selling at Immunome

In related news, CEO Clay B. Siegall purchased 150,000 shares of the business’s stock in a transaction dated Friday, January 31st. The stock was purchased at an average cost of $7.75 per share, with a total value of $1,162,500.00. Following the completion of the acquisition, the chief executive officer now directly owns 669,636 shares of the company’s stock, valued at approximately $5,189,679. The trade was a 28.87 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. 8.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Immunome

A number of large investors have recently made changes to their positions in the stock. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Immunome by 5.1% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 41,505 shares of the company’s stock worth $441,000 after acquiring an additional 2,005 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Immunome by 32.7% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 58,193 shares of the company’s stock worth $618,000 after acquiring an additional 14,328 shares during the period. Woodline Partners LP boosted its holdings in shares of Immunome by 6.1% in the fourth quarter. Woodline Partners LP now owns 980,925 shares of the company’s stock worth $10,417,000 after acquiring an additional 56,533 shares during the period. Two Sigma Advisers LP bought a new position in shares of Immunome in the fourth quarter worth $512,000. Finally, Two Sigma Investments LP bought a new position in shares of Immunome in the fourth quarter worth $1,640,000. 44.58% of the stock is owned by institutional investors.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.